IMPORTANT EQUITY ALERT: Lundin Law PC Announces an Investigation of Stemline Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm

LOS ANGELES--()--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (Nasdaq: STML) concerning possible violations of federal securities laws.

To get more information about this investigation, please click here, or contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.

On February 2, 2017, Bloomberg confirmed that a patient undergoing a clinical trial of Stemline’s cancer drug SL-401 died from a severe side effect, the third death related to SL-401 toxicity.

When this information was revealed to the public, the value of Stemline stock fell sharply, causing investors severe harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/